BiotechTube

Surufatinib

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors

Trial Timeline

Dec 7, 2015 → Jul 7, 2022

NCT ID
NCT02589821

About Surufatinib

Surufatinib is a phase 3 stage product being developed by HUTCHMED for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02589821. Target conditions include Neuroendocrine Tumors.

What happened to similar drugs?

6 of 15 similar drugs in Neuroendocrine Tumors were approved

Approved (6) Terminated (2) Active (8)
✅Everolimus (RAD001)NovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved
✅sunitinibPfizerApproved
✅lanreotide acetateIpsenApproved
✅lanreotide (Autogel formulation)IpsenApproved
🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT04814732Pre-clinicalCompleted
NCT05077384Phase 1/2Completed
NCT04579679Phase 2Terminated
NCT04372394Phase 1Completed
NCT02966821Phase 2Completed
NCT02614495Phase 2Completed
NCT02588170Phase 3Completed
NCT02589821Phase 3Completed
NCT02549937Phase 1/2Completed

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
LenvatinibEisaiPhase 2
35
AbemaciclibEli LillyPhase 2
39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
47
FamitinibJiangsu Hengrui MedicinePhase 2
27
68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3
47
OlaparibAstraZenecaPhase 2
27
AvelumabMerckPhase 1/2
32
PembrolizumabMerckPhase 2
27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-PyruvateMerckPhase 2
42
PembrolizumabMerckPhase 2
35
Pembrolizumab InjectionMerckPhase 2
27
Carboplatin + Cisplatin + Docetaxel + Etoposide + PembrolizumabMerckPhase 1
33
AvelumabMerckPhase 2
35
Pembrolizumab + LenvatinibMerckPhase 2
35
AvelumabMerckPhase 2
35
Pembrolizumab + Irinotecan + PaclitaxelMerckPhase 2
35
MK-0646MerckPhase 2
35